Celgene to acquire Pharmion

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Celgene to acquire Pharmion

SUMMIT, New Jersey—Celgene Corporation and Pharmion Corporation (Boulder, Colorado) have signed a definitive merger agreement by which Celgene will acquire all of the outstanding shares of Pharmion common stock. The acquisition furthers Celgene's strategy to become a global leader in the hematology/oncology field, the company said in a news release. The transaction brings together three cancer therapies: Celgene's Revlimid (lenalidomide) and Thalomid (thalidomide), and Pharmion's Vidaza (azacitadine).

Recent Videos
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content